Deutsche Bank AG Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Deutsche Bank AG boosted its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 34.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 42,804 shares of the company’s stock after purchasing an additional 10,873 shares during the quarter. Deutsche Bank AG owned about 0.06% of Zentalis Pharmaceuticals worth $130,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Corton Capital Inc. purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $32,000. Captrust Financial Advisors purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $33,000. Prudential Financial Inc. purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $39,000. Cerity Partners LLC purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $40,000. Finally, Ieq Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $46,000.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, April 30th. The shares were acquired at an average cost of $1.40 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now owns 281,192 shares in the company, valued at approximately $393,668.80. This trade represents a 8.07% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is currently owned by corporate insiders.

Zentalis Pharmaceuticals Stock Up 6.3%

Shares of ZNTL stock opened at $1.36 on Wednesday. The stock has a market cap of $97.85 million, a price-to-earnings ratio of -0.55 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $11.92. The firm’s 50 day moving average price is $1.29 and its two-hundred day moving average price is $2.12.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.67). On average, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wedbush restated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.